This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), AbCellera Biologics (ABCL) and Indivior (INDV)

Tipranks - Tipranks - Sat May 23, 6:52AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Hims & Hers Health (HIMS), AbCellera Biologics (ABCL) and Indivior (INDV).

Meet Samuel – Your Personal Investing Prophet

Hims & Hers Health (HIMS)

Truist Financial analyst Jailendra Singh reiterated a Hold rating on Hims & Hers Health today. The company’s shares closed last Thursday at $24.01.

According to TipRanks.com, Singh is ranked 0 out of 5 stars with an average return of -12.6% and a 35.9% success rate. Singh covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Fortrea Holdings Inc., and Revolution Medicines. ;'>

Currently, the analyst consensus on Hims & Hers Health is a Moderate Buy with an average price target of $28.97, which is a 27.0% upside from current levels. In a report issued on May 14, TipRanks – PerPlexity also downgraded the stock to Hold with a $25.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

AbCellera Biologics (ABCL)

Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on AbCellera Biologics today and set a price target of $12.00. The company’s shares closed last Thursday at $5.14.

According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of 18.4% and a 59.6% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Protagonist Therapeutics, and Madrigal Pharmaceuticals. ;'>

AbCellera Biologics has an analyst consensus of Strong Buy, with a price target consensus of $9.40, a 108.0% upside from current levels. In a report issued on May 11, TD Cowen also maintained a Buy rating on the stock.

Indivior (INDV)

Piper Sandler analyst David Amsellem reiterated a Buy rating on Indivior today and set a price target of $59.00. The company’s shares closed last Thursday at $37.46.

According to TipRanks.com, Amsellem is a 5-star analyst with an average return of 11.1% and a 57.9% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical. ;'>

Indivior has an analyst consensus of Strong Buy, with a price target consensus of $52.33.

Read More on HIMS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).